Conecte-se

Bibliografias temáticas / Lysosomal storage diseases / Teses / dissertações

Siga este link para ver outros tipos de publicações sobre o tema: Lysosomal storage diseases.

Teses / dissertações sobre o tema "Lysosomal storage diseases"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 25 de julho de 2025

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores trabalhos (teses / dissertações) para estudos sobre o assunto "Lysosomal storage diseases".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja as teses / dissertações das mais diversas áreas científicas e compile uma bibliografia correta.

1

Roy, Elise. "Cell disorders in lysosomal storage diseases." Phd thesis, Université René Descartes - Paris V, 2012. http://tel.archives-ouvertes.fr/tel-00683248.

Texto completo da fonte

Resumo:

Mucopolysaccharidosis type IIIB (MPSIIIB) is a lysosomal storage disease (LSD) characterized by accumulation of heparan sulfate oligosaccharides (HSO), which results in progressive mental retardation, neurodegeneration and premature death in children. The underlying mechanisms are poorly understood. Coming to a better understanding of the pathophysiology of MPSIIIB has become a necessity to assess the efficacy of gene therapy treatment regarding loss of neuronal plasticity, and to define the best conditions for treatment. To address the link between HSO accumulation and downstream pathological

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Chen, Chun-Wu. "Defective iron homeostasis in lysosomal storage diseases." Thesis, University of Oxford, 2013. http://ora.ox.ac.uk/objects/uuid:5127c241-be64-4990-bef5-70e15d391394.

Texto completo da fonte

Resumo:

Niemann-Pick type Cl (NPC1) disease is a neurodegenerative lysosomal storage disorder characterized by the accumulation of multiple lipids in the late endosome/lysosomal system and reduced acidic store calcium levels. Since the lysosomal system is involved in regulating aspects of transition metal ion homeostasis and its intracellular compartmentalization, we have investigated whether there are metal ion metabolism defects and haematological abnormalities in NPC1 disease. We have identified multiple haematological changes, including decreased haematocrit, haemoglobin and mean corpuscular haemo

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Ross, Colin J. D. "Immuno-isolation gene therapy for lysosomal storage disease /." *McMaster only, 2001.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Rigal, Nathalie [Verfasser]. "Improving enzyme replacement therapy for lysosomal storage diseases / Nathalie Rigal." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2018. http://d-nb.info/115576093X/34.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Lewis, Martin David. "Human lysosomal sulphate transport." Title page, contents and abstract only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phl6752.pdf.

Texto completo da fonte

Resumo:

Addendum inserted at back Includes bibliographical references (leaves 266-287). 1. Introduction -- 2. Materials and general methods -- 3. Characterisation and partial purification of the lysosomal sulphate transporter -- 4. Identification of proteins involved in lysosomal sulphate transport -- 5. The relationship between a sulphate anion transporter family and the lysosomal sulphate transporter -- 6. Investigation of sulphate transport in human skin fibroblasts -- 7. Concluding remarks

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Kanju, Patrick M. Suppiramaniam Vishnu. "Synaptic glutamate receptor dysfunction in tissue and animal models of Alzheimer's disease." Auburn, Ala., 2005. http://repo.lib.auburn.edu/2005%20Summer/doctoral/KANJU_PATRICK_11.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Champigny, Marc J. Igdoura Suleiman. "Transcriptional regulation of neu1 expression: Implications for lysosomal storage disease /." *McMaster only, 2005.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Maalouf, Katia Ghandour [Verfasser]. "Role of lipid rafts in the pathophysiology of lysosomal storage diseases / Katia Ghandour Maalouf." Hannover : Technische Informationsbibliothek und Universitätsbibliothek Hannover (TIB), 2012. http://nbn-resolving.de/urn:nbn:de:gbv:089-7259318337.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Ghandour, Maalouf Katia [Verfasser]. "Role of lipid rafts in the pathophysiology of lysosomal storage diseases / Katia Ghandour Maalouf." Hannover : Technische Informationsbibliothek und Universitätsbibliothek Hannover (TIB), 2012. http://d-nb.info/1029515352/34.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Gray, James Andrew Russell. "Modulating the heat-shock response : a potential therapy for lysosomal storage disorders." Thesis, University of Oxford, 2014. https://ora.ox.ac.uk/objects/uuid:d9b746c9-9026-4a6e-97b5-00bb848100d7.

Texto completo da fonte

Resumo:

Lysosomal storage disorders (LSDs) comprise a broad disease group of inherited metabolic disorders, the majority of which are associated with CNS pathology, significant disability and reductions in life expectancy. LSDs are caused by mutations in genes encoding proteins critical for the correct functioning of lysosomal homeostasis. The disruption of lysosomal homeostasis results in the abnormal accumulation of lysosomal content, initiating intracellular pathological events, including calcium dysregulation and lysosomal membrane permeablisation (LMP) affecting cell function and inducing cellula

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Gliddon, Briony Lee. "Enzyme replacement therapy in a murine model of mucopolysaccharidosis type IIIA /." Title page, contents and abstract only, 2002. http://web4.library.adelaide.edu.au/theses/09PH/09phg5595.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Crawley, Allison Catherine. "Enzyme replacement therapy in a feline model of mucopolysaccharidosis type VI /." Title page, contents and abstract only, 1998. http://web4.library.adelaide.edu.au/theses/09PH/09phc9107.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Li, Yijun. "Detection of enzyme deficient genetic diseases by electrospray ionization mass spectrometry /." Thesis, Connect to this title online; UW restricted, 2004. http://hdl.handle.net/1773/11577.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Kim, A. Rang M. S. "Discontinuing Enzyme Replacement Therapy in Patients with Lysosomal Storage Diseases due to Significant Clinical Decline." University of Cincinnati / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1396522371.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Yogalingam, Gouri. "Molecular characterisation of feline MPS VI and evaluation of gene therapy /." Title page, contents and abstract only, 1998. http://web4.library.adelaide.edu.au/theses/09PH/09phy54.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Freeman, Craig. "The lysosomal degradation of heparan sulphate : a comparative study of the physical and catalytic properties of the heparan sulphate degradative enzymes /." Title page, contents and abstract only, 1991. http://web4.library.adelaide.edu.au/theses/09PH/09phf855.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Zarrinkalam, Krystyna. "Characterisation of osteoblast function in a feline model of mucopolysaccharidosis type VI." Title page, contents and introduction only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phz38.pdf.

Texto completo da fonte

Resumo:

Addenda slip inserted in back. Includes bibliographical references (leaves 178-231). To further the understanding of the molecular mechanisms that contribute to the skeletal pathology of mucopolysaccharidosis type VI and to investigate the production of organic matrix by mucopolysaccharidosis VI osteoblasts

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Maghe, Clément. "Elucidating the Vulnerability of Glioblastoma Stem-like Cells to Lysosomal Dysfunctions." Electronic Thesis or Diss., Nantes Université, 2023. http://www.theses.fr/2023NANU1035.

Texto completo da fonte

Resumo:

Le glioblastome (GB) est le cancer du système nerveux central de l’adulte le plus commun et le plus meurtrier. Malgré un traitement invasif de résection chirurgicale suivi de séances de radio- et de chimiothérapies, la survie des patients atteints difficilement les 15 mois. Cette agressivité est considérée comme liée notamment à la présence de cellules souches cancéreuses appelées cellules de type souche de glioblastome, ou GSCs. Ces cellules, impliquées dans l’initiation, la croissance, et la récurrence du GB, sont considérées comme des cibles préférentielles. Les lysosomes jouent un rôle cri

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Harvey, John Steven. "Metachromatic leukodystrophy : the role of non-pathogenic sequence variants in the causation of disease /." Title page, contents and abstract only, 1996. http://web4.library.adelaide.edu.au/theses/09PH/09phh341.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Gomez, Grau Marta. "Models and therapeutic approaches for Niemann-Pick (A/B and C) and other lysosomal storage disorders." Doctoral thesis, Universitat de Barcelona, 2015. http://hdl.handle.net/10803/385854.

Texto completo da fonte

Resumo:

Lysosomal storage disorders (LSDs) are a group of more than 50 different genetic disorders due to the lack of degradation of substrates within lysosomes. Most of them are caused by mutations in genes coding for lysosomal hydrolases. LSDs are mainly inherited in an autosomal recessive manner. Although in the last 25 years there has been much effort and progress to develop therapies aiming the correction of metabolic defects for these diseases, yet there is no effective therapy for many of them, and patients are exclusively treated with supportive care. For several non-neurological LSDs, en

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Zaccariotto, Eva. "The blood-brain barrier and San Filippo Syndrome: a model for pathophisiology studies of CNS in lysosomal storage diseases." Doctoral thesis, Università degli studi di Padova, 2009. http://hdl.handle.net/11577/3426008.

Texto completo da fonte

Resumo:

The lysosomal storage diseases (LSDs) are a large and heterogeneous group of disorders resulting from defects in various aspects of lysosomal function. They commonly afflict infants and young children and mostly involve pathology of the brain which is currently untreatable when it’s present. All animals with a well developed central nervous system (CNS) have a blood-brain barrier (BBB) that largely isolates the brain from alterations in the composition of the blood stream and the continuous changes that take place in these general body fluids. This BBB also impedes the global CNS delivery of m

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Litjens, Tom. "The molecular genetics of mucopolysaccharidosis type VI /." Title page, contents and abstract only, 1994. http://web4.library.adelaide.edu.au/theses/09PH/09phl776.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

White, Elaine Joanna. "Evaluation of receptor-mediated gene transfer using an integrin-targeting vector as a potential form of therapy for lysosomal storage diseases." Thesis, University College London (University of London), 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.340643.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Gerber, Scott Anthony. "Direct profiling of multiple enzymes in human cell lysates by affinity chromatography/electrospray ionization mass spectrometry : application to clinical enzymology /." Thesis, Connect to this title online; UW restricted, 2001. http://hdl.handle.net/1773/8490.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Weismann, Cara M. "Approaches and Considerations Towards a Safe and Effective Adeno-Associated Virus Mediated Therapeutic Intervention for GM1-Gangliosidosis: A Dissertation." eScholarship@UMMS, 2014. http://escholarship.umassmed.edu/gsbs_diss/767.

Texto completo da fonte

Resumo:

GM1 gangliosidosis is a lysosomal storage disorder caused by a deficiency in the catabolizing enzyme β-galactosidase (βgal). This leads to accumulation of GM1-ganglioside (GM1) in the lysosome inducing ER stress and cell death. GM1 gangliosidosis is primarily a disorder of the central nervous system (CNS) with peripheral organ involvement. In this work we report two major findings, 1) systemic treatment of GM1 gangliosidosis with an adenoassociated virus (AAV9) encoding mouse-βgal (mβgal) in a GM1 gangliosidosis mouse model (βGal-/-), and 2) an investigation into an intracranial injection of a

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Da, Silva Afitz. "Glycovecteurs pour le ciblage thérapeutique d'une maladie rare lysosomale : la maladie de Pompe." Thesis, Montpellier, 2017. http://www.theses.fr/2017MONTT001.

Texto completo da fonte

Resumo:

Sur la cinquantaine de maladies rares lysosomales, seules 8 peuvent être traitées par enzymothérapie substitutive avec plus ou moins d’efficacité. Il y a donc un réel besoin de développer de nouveaux traitements mais aussi de mieux caractériser les causes de ces maladies. Durant cette thèse nous nous sommes intéressés à la maladie de Pompe qui résulte de l’absence ou de la carence en enzyme lysosomale alpha-glucosidase acide (GAA) responsable de la dégradation du glycogène en glucose dans de nombreux tissus. Actuellement seule la forme infantile de cette maladie peut être traitée alors que la

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Leishman, Alison Jane. "Harnessing the immunomodulatory capacity of dendritic cells differentiated from human induced pluripotent stem cells and the therapeutic potential of dendritic cell-derived exosomes for the treatment of lysosomal storage diseases." Thesis, University of Oxford, 2015. https://ora.ox.ac.uk/objects/uuid:97f6791f-ff69-4645-9a3d-2ff23ce69529.

Texto completo da fonte

Resumo:

Lysosomal storage diseases (LSDs) are a collection of disorders that feature the pathological accumulation of substrate frequently due to an enzymatic defect within the lysosomes. The most effective treatment regime for LSDs is enzyme replacement therapy. However, this treatment has faced two main challenges which have limited its treatment efficacy and clinical impact. One challenge constitutes the potential immunogenicity of the replaced enzyme, which can lead to the induction of an antibody response that prevents its effective targeting. Therefore, this thesis investigated the potential to

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Leishman, Alison Jane. "Harnessing the immonomodulatory capacity of dendritic cells differentiated from human induced pluripotent stem cells and the therapeutic potential of dendritic cell-derived exosomes for the treatment of lysosomal storage diseases." Thesis, University of Oxford, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711748.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Wang, Ding. "Application of mass spectrometry in enzyme deficiency assay for newborn screening purpose /." Thesis, Connect to this title online; UW restricted, 2006. http://hdl.handle.net/1773/11557.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Bender, Fernanda. "Triagem neonatal para mucopolissacaridose tipo VI (Síndrome de Maroteux-Lamy) em uma região com alta incidência da doença." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2011. http://hdl.handle.net/10183/48987.

Texto completo da fonte

Resumo:

A mucopolissacaridose tipo VI (MPS VI) ou Síndrome de Maroteaux-Lamy, é uma doença autossômica recessiva causada pela deficiência da enzima lisossomal Nacetilgalactosamina- 4-sulfatase (ARSB), a qual resulta no armazenamento lisossômico de dermatan sufato em vários tecidos e órgãos, dando origem a uma condição clínica de espectro variável, desde formas mais graves até formas mais atenuadas. O acúmulo de substrato não degradado causa um importante comprometimento ósseo, problemas respiratórios, baixa estatura e outros problemas, afetando os olhos, o coração e outros órgãos. Embora a síndrome de

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

SAMARANI, MAURA. "CELL DAMAGE INDUCED BY LYSOSOMAL IMPAIRMENT: STUDY OF THE ROLE OF PLASMA MEMBRANE SPHINGOLIPIDS." Doctoral thesis, Università degli Studi di Milano, 2017. http://hdl.handle.net/2434/482301.

Texto completo da fonte

Resumo:

Lysosomes are the principal site of the catabolism of sphingolipids, a class of bioactive lipids mainly associated with the external leaflet of cell plasma membrane. Several lines of evidence support a direct correlation between modifications in sphingolipid pattern and the activation of specific signaling pathways, including apoptosis and autophagy. Loss-of-function mutations in genes coding for lysosomal enzymes involved in sphingolipid catabolism result in severe clinical manifestations called sphingolipidoses. These pathologies belong to the group of Lysosomal Storage Diseases and are char

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Mason, Lyndel Ann. "Expression variation in lysosomal storage disorder genes." Thesis, Queensland University of Technology, 2006. https://eprints.qut.edu.au/16240/1/Lyndel_Mason_Thesis.pdf.

Texto completo da fonte

Resumo:

Metachromatic leukodystrophy (MLD) and Gaucher disease (GD) are caused by a deficiency of arylsulphatase A (ASA) and b-glucocerebrosidase (GBA), respectively. They are lysosomal storage disorders with a heterogeneous clinical spectrum encompassing visceral, skeletal and neurologic involvement resulting in high morbidity and mortality. The overall aim of this study is to elucidate the genetic component/s of high ASA and GBA enzyme activity in normal healthy individuals with the ultimate goal of using this information to produce greater protein activity from a recombinant protein. A wide variati

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Mason, Lyndel Ann. "Expression variation in lysosomal storage disorder genes." Queensland University of Technology, 2006. http://eprints.qut.edu.au/16240/.

Texto completo da fonte

Resumo:

Metachromatic leukodystrophy (MLD) and Gaucher disease (GD) are caused by a deficiency of arylsulphatase A (ASA) and b-glucocerebrosidase (GBA), respectively. They are lysosomal storage disorders with a heterogeneous clinical spectrum encompassing visceral, skeletal and neurologic involvement resulting in high morbidity and mortality. The overall aim of this study is to elucidate the genetic component/s of high ASA and GBA enzyme activity in normal healthy individuals with the ultimate goal of using this information to produce greater protein activity from a recombinant protein. A wide variati

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Rouvière, Laura. "Transfert de gènes dans un modèle murin de la maladie de Sandhoff à l'aide d'un vecteur scAAV9 : intérêt d'une double voie d'administration ?" Thesis, Sorbonne Paris Cité, 2017. http://www.theses.fr/2017USPCB052/document.

Texto completo da fonte

Resumo:

La maladie de Sandhoff est une maladie génétique rare due à des mutations du gène HEXB. Elle se caractérise par un double déficit en hexosaminidase A (αβ) et B (ββ), responsable d’une accumulation de ganglioside GM2 essentiellement dans le système nerveux central (SNC). Cliniquement, la maladie débute dès les premiers mois de vie et le décès survient vers l’âge de 3 ans. A ce jour, aucun traitement n’est disponible pour cette maladie. Le modèle murin obtenu par invalidation du gène Hexb est un bon outil pour le développement d’approches thérapeutiques, car il présente un phénotype proche de la

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Salgues, Frédéric. "Ciblage des lysosomes pour la thérapie enzymatique substitutive ou pour la thérapie photodynamique." Thesis, Montpellier 2, 2011. http://www.theses.fr/2011MON20148.

Texto completo da fonte

Resumo:

Le récepteur du mannose-6-phosphate cation indépendant (RM6P-CI) permet l'endocytose puis le transfert de molécules porteuses du marqueur M6P vers les lysosomes. Pour améliorer à la fois l'affinité pour le RM6P-CI et la stabilité du résidu M6P, nous avons procédé à la synthèse d'analogues isostères stables et fonctionnalisés en position anomère pour permettre un couplage efficace à des molécules d'intérêt thérapeutique. Tout d'abord un couplage à des enzymes recombinantes humaines a été réalisé. Le remodelage de la partie oligosaccharidique de l'enzyme lysosomale GAA, dont la déficience est re

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Munõz, Rojas Maria Verônica. "Tratamento inovador da compressão medular com reposição enzimática intratecal nas mucopolissacaridoses tipos I e VI : relato de uma série de casos." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2010. http://hdl.handle.net/10183/29034.

Texto completo da fonte

Resumo:

As mucopolissacaridoses apresentam uma história natural progressiva, causada por defeitos no metabolismo dos glicosaminoglicanos. Frequentemente graves, as mucopolissacaridoses encurtam de forma considerável a expectativa de vida do paciente. Apesar de que em muitos casos a função intelectual é normal, morbidade neurológica considerável pode ser causada por compressão medular secundária ao acúmulo de glicosaminoglicanos nas meninges. O tratamento deste problema pode requerer a descompressão medular através de laminectomia cervical. A terapia de reposição enzimática endovenosa, para o tratament

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Manwaring, V. J. "The identification of potential diagnostic biomarkers amd disease mechanisms in lysosomal storage disorders." Thesis, University College London (University of London), 2014. http://discovery.ucl.ac.uk/1427920/.

Texto completo da fonte

Resumo:

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A. The resultant progressive intracellular accumulation of the glycosphingolipids globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) are the source of a variety of clinical consequences. Biomarkers capable of detecting FD at an early stage of disease progression and that enable monitoring of response to treatment are required urgently. Using label-free quantitative proteomics two potential biomarkers, proactivator polypeptide and ganglioside GM2 activator prote

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Boomkamp, Stephanie. "Lysosomal storage and pathogenesis in a novel in vitro cellular model of Sandhoff disease." Thesis, University of Oxford, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.496832.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Rockwell, Hannah. "AAV-Mediated Gene Delivery Corrects CNS Lysosomal Storage in Cats with Juvenile Sandhoff Disease." Thesis, Boston College, 2013. http://hdl.handle.net/2345/3929.

Texto completo da fonte

Resumo:

Thesis advisor: Thomas N. Seyfried<br>Sandhoff Disease (SD) is an autosomal recessive neurodegenerative disease caused by a mutation in the Hexb gene for the β-subunit of β-hexosaminidase A, resulting in the inability to catabolize ganglioside GM2 within the lysosomes. SD presents with an accumulation of GM2 and its asialo derivative GA2 primarily in the CNS. Myelin-enriched glycolipids, cerebrosides and sulfatides, are also decreased in SD corresponding with dysmyelination. At present, no treatment exists for SD. Previous studies have shown the therapeutic benefit of using adeno-associated vi

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Haslett, Luke. "Lysosomal storage disorders and neurodegenerative disease : related mechanisms of pathogenesis and identification of novel therapeutic targets." Thesis, Cardiff University, 2015. http://orca.cf.ac.uk/89191/.

Texto completo da fonte

Resumo:

Lysosomal storage disorders (LSDs) are rare diseases caused by inherited mutations in genes coding for proteins of the endolysosomal system. The lysosome is an organelle responsible for the degradation of dysfunctional organelles and for the catabolism, and subsequent recycling, of macromolecules within the cell. When this process becomes defective the substrates of lysosomal catabolism accumulate; these can include lipids, proteins, polysaccharides, nucleotides and diverse combinations of all three. The phenotypic spectrum of these diseases in isolation, and even more so as a group, is extrem

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Hermans, Monique Maria Petra. "Structural and functional analysis of lysosomal [alpha]-glucosidase in relation to glycogen storage disease type II." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 1993. http://hdl.handle.net/1765/13746.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Wolf, Heike [Verfasser], Torben [Akademischer Betreuer] Lübke, and von Mollard Gabriele [Akademischer Betreuer] Fischer. "The lysosomal storage disease fucosidosis: towards enzyme replacement therapy / Heike Wolf ; Torben Lübke, Gabriele Fischer von Mollard." Bielefeld : Universitätsbibliothek Bielefeld, 2016. http://d-nb.info/1118688295/34.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Fletcher, Jessica Louise. "Pathophysiology of canine fucosidosis." Thesis, The University of Sydney, 2013. http://hdl.handle.net/2123/10420.

Texto completo da fonte

Resumo:

Pathophysiology of Canine Fucosidosis by Jessica L Fletcher Understanding processes involved in the onset and progression of fucosidosis, a childhood neurodegenerative lysosomal storage disease, is critical to the development of effective treatment. Fucosidosis is caused by deficiency of the lysosomal hydrolase α-L-fucosidase due to inherited mutations in the FUCA1 gene. Canine fucosidosis, the only preserved animal model, was used to characterise preclinical pathophysiology, to establish potential markers of disease progression and test their capacity to measure responses to early therapy. S

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Mütze, Ulrike, Friederike Bürger, Jessica Hoffmann, et al. "Multigene panel next generation sequencing in a patient with cherry red macular spot." Universitätsbibliothek Leipzig, 2017. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-217944.

Texto completo da fonte

Resumo:

Background: Lysosomal storage diseases (LSD) often manifest with cherry red macular spots. Diagnosis is based on clinical features and specific biochemical and enzymatic patterns. In uncertain cases, genetic testing with next generation sequencing can establish a diagnosis, especially in milder or atypical phenotypes. We report on the diagnostic work-up in a boy with sialidosis type I, presenting initially with marked cherry red macular spots but non-specific urinary oligosaccharide patterns and unusually mild excretion of bound sialic acid. Methods: Biochemical, enzymatic and genetic tests we

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Del, Grosso Ambra. "Nanoparticle-mediated enzyme replacement therapy and autophagy modulation in Krabbe disease." Doctoral thesis, Scuola Normale Superiore, 2020. http://hdl.handle.net/11384/85899.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Zancan, Ilaria. "Understanding bone alterations in Gaucher disease using the zebrafish animal model: development of a novel pathogenetic paradigm for lysosomal storage disorders." Doctoral thesis, Università degli studi di Padova, 2015. http://hdl.handle.net/11577/3424231.

Texto completo da fonte

Resumo:

Lysosomal storage disorders (LSDs) are rare inherited metabolic disorders due to a deficiency of specific lysosomal enzymes or transporters. Almost 50 genetic disorders caused by deficiencies of lysosomal and non-lysosomal proteins are known nowadays, collectively with an incidence of ~1/7000 newborns in the worldwide population. Dysfunctions of such lysosomal enzymes or transporters can lead to several consequences that include incomplete degradation and/or recycling of intracellular molecules. Despite lysosomal proteins are present in almost all type of cells, the accumulation of undegraded

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Al, Eisa Nada. "Evaluation of new therapies in Niemann-Pick type C disease." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:1538a0d6-b08e-444c-900d-de3ea3834ca5.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Peterneva, Ksenia. "Determining the mechanism of pathogenesis of mucolipidosis type IV and related lysosomal storage disorders for development of novel therapies." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:321b1da6-0033-4230-b047-b643e5ea3e60.

Texto completo da fonte

Resumo:

Mucolipidosis type IV (MLIV) is a rare, autosomal recessive, neurodegenerative, lysosomal storage disorder. MLIV is caused by mutations in a gene (MCOLN1) encoding a TRP channel family member known as Mucolipin 1 or TRPML1. TRPML1 is a lysosomal transmembrane protein that appears to be required for normal lysosomal pH regulation, recycling of molecules and membrane reorganisation including lysosomal biogenesis, fusion and exocytosis. The exact function of the channel is unknown but it is permeable to multiple ions including Ca<sup>2+</sup>, Na<sup>+</sup> and K<sup>+</sup>, possibly also Fe<su

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Mütze, Ulrike, Friederike Bürger, Jessica Hoffmann, et al. "Multigene panel next generation sequencing in a patient with cherry red macular spot: identification of two novelmutations in NEU1 gene causing sialidosis type I associated with mild to unspecific biochemical and enzymatic findings." Molecular Genetics and Metabolism Reports 10 (2017) 1–4 doi:10.1016/j.ymgmr.2016.11.004, 2016. https://ul.qucosa.de/id/qucosa%3A15254.

Texto completo da fonte

Resumo:

Background: Lysosomal storage diseases (LSD) often manifest with cherry red macular spots. Diagnosis is based on clinical features and specific biochemical and enzymatic patterns. In uncertain cases, genetic testing with next generation sequencing can establish a diagnosis, especially in milder or atypical phenotypes. We report on the diagnostic work-up in a boy with sialidosis type I, presenting initially with marked cherry red macular spots but non-specific urinary oligosaccharide patterns and unusually mild excretion of bound sialic acid. Methods: Biochemical, enzymatic and genetic tests we

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Langford-Smith, Alexander William Walker. "Lentiviral vector mediated haematopoietic stem cell gene therapy for mucopolysaccharidosis type IIIA." Thesis, University of Manchester, 2012. https://www.research.manchester.ac.uk/portal/en/theses/lentiviral-vector-mediated-haematopoietic-stem-cell-gene-therapy-for-mucopolysaccharidosis-type-iiia(89f8e108-58f3-42bb-8b80-0e0a1fe45fd7).html.

Texto completo da fonte

Resumo:

Mucopolysaccharidosis type III (Sanfilippo) is comprised of four phenotypically similar lysosomal storage disorders (MPS IIIA-D) caused by the deficiency of enzymes that catabolise heparan sulphate (HS). Progressive accumulation of HS results in abnormal behaviour, progressive cognitive and motor impairment and death in mid-teens. There are currently no treatments for MPS III. To assess the effect of novel therapeutics in the mouse models of MPS III it is necessary to examine the effect on primary storage of HS, secondary storage and behaviour. The reported behaviour of MPS IIIA and B mice is

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!